Vivalytic | SARS-CoV-2 Pooling Test

Home - vivalytic

Vivalytic | SARS-CoV-2 Pooling Test

Vivalytic | SARS-CoV-2 Pooling Test

Detecting SARS-CoV-2 (COVID-19)

Detecting SARS-CoV-2 (COVID-19) from up to 5 Pooled Samples Simultaneously

  • null
    Detection from real-time PCR via Nasopharyngeal and/or Oropharyngeal swab
  • null
    Up to 5 patient samples may be pooled and added to a single cartridge targeting the E gene sequence
  • null
    The SARS-CoV-2 pooling test has recently received CE marking
  • null
    Simple and easy to use POC analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
  • null
    Rapid turnaround from sample entry to result, capable of testing up to 160 samples a day
  • null
    Convenient 4 step process from sample entry to results. No laboratory training required

SARS-CoV-2 Pooling (COVID-19) is a rapid real time PCR test cartridge, providing clear and concise results in a timely manner, direct at the point of care. This enables the patient to take the recommended safety precautions without delay. The pooling could be done at the level of a ward, medical speciality, social bubble, or group of colleagues. It has potential for use in other settings, such as pre-operative screening, schools and universities, prisons, nursing homes, primary care, and large workplaces. Sample pooling allows more people to be tested quickly using fewer testing resources.

In collaboration with Bosch, we are proud to release not only a rapid testing solution for the detection of SARS-CoV-2 (COVID-19) but an accelerated mass testing solution to effectively and efficiently monitor and detect viral infection from the offset with an aim of minimising the rise in infections globally. The new SARS-CoV-2 pooling test will allow users to test up to 160 samples a day and has sensitivity of 98% and a specificity of 100% – a world’s first! Highly sensitive assays allow for laboratories to accurately detect low positive samples, enabling for effective identification of positive COVID-19 cases in a timely manner.

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

SARS-CoV-2 Rapid Test

Vivalytic

Vivalytic Test Menu


Vivalytic | Sexually Transmitted Infection Array

Vivalytic | Sexually Transmitted Infection Array

1 Sample | 1 Test | 10 Infections

Comprehensive Sexual Health Profile

  • null
    Detecting 10 bacterial, viral and protozoan infections
  • null
    Sample to answer, cartridge based molecular diagnostics at the point of care. Powered by Randox Biochip Technology
  • null
    The STI array has recently received CE marking
  • null
    Simple and easy to use analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
  • null
    Rapid turnaround time of just 2 hours from sample entry to result
  • null
    Convenient 4 step process from sample entry to results. No laboratory training required

The Sexually Transmitted Infection (STI) array is the broadest multiplex cartridge-based STI test on the market simultaneously detecting 7 bacterial,  2 viral and 1 protozoan infection for a comprehensive sexual health profile.

Globally, each day over 1 million people are exposed to an STI, many of who will not know they have an infection as many STI’s are asymptomatic whilst some individuals will display similar or overlapping symptoms, therefore co-infections may remain undiagnosed. Designed to offer a complete sexual health profile with an aim of prevention and control, the Vivalytic STI array can be used to diagnose existing infections whilst any identifying co-infections.

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

Vivalytic Test Cartridges

Vivalytic

Vivalytic Test Menu


New 39-minute COVID test available on Randox-Bosch Vivalytic

News       About Us       SARS-CoV-2 Rapid Test

 

02 October 2020

 

New 39-minute COVID test available on Randox-Bosch Vivalytic

  • The world’s fastest PCR based SARS-CoV-2 test for the point of care delivers reliable results in 39 minutes.
  • Has a sensitivity of 98 percent and a specificity of 100 percent.
  • Simultaneous testing of five people with one cartridge by pooling will be available from early October.
  • Work is in progress to further reduce time to result.

A rapid new coronavirus test, which provides results for Covid-19 in just 39 minutes, is now available on the Vivalytic, a point of care platform brought to market by Randox Laboratories and Bosch.

The test for detection of the SARS-CoV-2 pathogen, is currently the fastest PCR test (the gold standard of test methods) worldwide, and is predestined for decentralized use in mobile test centres at service stations or in airports, so that people who take the test can obtain a reliable result while at the testing site.

Available now in Europe, the CE-approved test, which has a sensitivity of 98 percent and a specificity of 100 percent, helps avoid time in quarantine, relieve laboratories, and make travel and work safer again.

“Rapid and accurate testing plays a crucial role in identifying cases of Covid-19 – to contain any outbreaks and limit the spread of the virus,” says Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences.

 “This new rapid test will be a game-changer in the coronavirus testing landscape by allowing patients to receive their results at the point of care faster than ever before.”

Randox and Bosch launched the first rapid test for the Vivalytic analyser at the end of March, after just six weeks’ development.

As a multiplex test, it simultaneously checks samples for the SARS-CoV-2 virus as well as nine other respiratory diseases in two and a half hours, whereas the new accelerated test is exclusively for SARS-CoV-2.

“With our different coronavirus tests and variable analysis strategies, we open up a range of testing scenarios with a Vivalytic device – from screening all the way to supporting differential diagnosis for similar symptoms,” says Marc Meier, president of Bosch Healthcare Solutions GmbH.

And development work for Covid tests on the Vivalytic is ongoing: as of early October 2020, by pooling samples together it will be possible to simultaneously evaluate five samples in one test cartridge and at a comparable speed – a world first.

This will increase available testing capacity, by enabling fully automated processing of more than 160 samples a day using a Vivalytic device.

Key Benefits of SARS-CoV-2 test on Vivalytic point of care platform

The advantages of the rapid SARS-CoV-2 test on Vivalytic lie not only in speedy analysis, but also in ease of use. A sample is taken from the nose or throat using a swab, and placed in the test cartridge. Then the cartridge, which contains all the reagents required for the test, is inserted into the Vivalytic device for automated analysis.

  • Turnaround time of 39 mins from sample entry to result.
  • The SARS-CoV-2 rapid test has recently received CE marking.
  • The SARS-CoV-2 pooling test can run up to 5 samples on-board one single cartridge.
  • Easy 4-step user-friendly process from sample entry to result. Minimal training required.
  • Detection from real-time PCR from Nasopharyngeal and/or Oropharyngeal swab.
  • Suitable for use in any laboratory and non-laboratory settings.

The development of the new Vivalytic PCR singleplex test is part of a research and development project funded by the German Federal Ministry of Education and Research (BMBF).

For more information please contact marketing@randox.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Vivalytic | Test Menu

Vivalytic | Test Menu

Detection at the Point Of Care

Detect Infections Now

  • null

    SARS-CoV-2

  • null

    Respiratory

  • null

    Genitourinary

  • null

    Hospital Acquired Infections

Respiratory

  • Virial Respiratory Infection
  • SARS-CoV-2 Rapid Test
  • SARS-CoV-2 Pooling
  • Respiratory Tract Infection
  • Flu A, B, & RSV
  • Chronic Lung Disease

VIRUSES
SARS-CoV-2 (COVID-19)Sarbecovirus
(SARS, SARS like, SARS-CoV-2)
Influenza A
Coronavirus 229E/NL63Adenovirus A/B/C/D/EInfluenza B
Coronavirus OC43/HKUIEnterovirus A/B/CRhinovirus A/B
Middle East Respiratory
Syndrome Coronavirus (MERS-CoV)
VIRUSES
SARS-CoV-2 (COVID-19)
VIRUSES
SARS-CoV-2 (COVID-19)

 

VIRUSES
Influenza ACoronavirus OC43/HKUIParainfluenza virus 3
Influenza BEnterovirus A/B/CParainfluenza virus 4
Adenovirus A/B/C/D/EMetapneumovirusRespiratory syncytial virus A/B
Bocavirus 1/2/3Parainfluenza virus 1Rhinovirus A/B/C
Coronavirus 229E/NL63Parainfluenza virus 2
BACTERIA
Bordetella parapertussis Haemophilus influenzaeMycoplasma pneumoniae
Bordetella pertussisLegionella pneumophilaStreptococcus pneumoniae
Chlamydophila pneumoniaeMoraxella catarrhalis
VIRUSES
Influenza AInfluenza BRespiratory Syncytial Virus (RSV)
VIRUSES
AdenovirusRespiratory syncytial virus BInfluenza B
MetapneumovirusRhinovirus A/B/C
Respiratory syncytial virus AInfluenza virus A
BACTERIA
Achromobacter xylosoxidans Moraxella catarrhalis Pseudomonas aeruginosa
Bordetella pertussis Mycoplasma pneumoniae Staphylococcus aureus
Burkholderia cepacia complex (21 spp) Non-tuberculous mycobacterium (15 spp Stenotrophomonas maltophila
Burkholderia Cenocepacia Mycobacterium abscessus subgroup (4 spp) Streptococcus pneumoniae (21spp)
Burkholderia multivorans Mycobacterium avium complex (4 spp) Streptococcus species (19 spp)
Chlamydia pneumoniae Pandoraea species (5spp) Veillonella species (3 spp)
Haemophilus influenza Prevotella species (16 spp)
FUNGI
Aspergillus fumigatus Candida albicans Exophialia dermatitidis
Scedosporium species (7 spp)
ANTIBIOTIC RESISTANCE MARKERS
mecA (incl MRSA)

Genitourinary

  • Sexually Transmitted Infection
  • Urinary Tract Infection
VIRUSES
Neisseria Gonorrhoeae (NG)Haemophilus Ducreyi (HD)
Mycoplasma Genitalium (MG)Mycoplasma Hominis (MH)
Ureaplasma Urealyticum (UU)Treponema Pallidum (TP)
Chlamydia Trachomatis (CT)Herpes Simplex virus 1(HSV-1)
Trichomonas Vaginalis (TV)Herpes Simplex virus 2(HSV-2)
BACTERIA
Citrobacter freundii Klebsiella oxytoca Serratia marcescens
Citrobacter koseri Klebsiella pneumoniae Staphylococcus aureus
Klebsiella aerogenes Morganella morganii Staphylococcus epidermidis
Enterobacter cloacae Proteus spp. Staphylococcus saprophyticus
Enterococcus faecalis Pseudomonas aeruginosa Streptococcus agalactiae (GBS)
Enterococcus faecium Providencia rettgeri
FUNGUS
Candida albicans
ANTIOBIOTIC RESISTANCE MARKERS
mecA (incl MRSA) Trimethoprim Resistance 3 Van A (Vancomycin Resistance A)
Trimethoprim Resistance 1 Trimethoprim Resistance 4 Van B (Vancomycin Resistance B)
Trimethoprim Resistance 2 Trimethoprim Resistance 5

Hospital Acquired Infections

  • MRSA
BACTERIA
Methicillin-resistant Staphylococcus aureus (MRSA)Methicillin-sensitive Staphylococcus aureus (MSSA) Methicillin-resistant coagulase-negative Staphylococci (MRCoNS)

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Vivalytic Testing Cartridges

VRI Array

Vivalytic

SARS-CoV-2 Rapid Test


Vivalytic | Test Cartridges

Vivalytic | Cartridges

Powered by Biochip Technology

Simple & Accurate POC Molecular Diagnostics

  • null
    Unique test menu covering a diverse range of respiratory, genitourinary and hospital acquired infections including SARS-CoV-2 (COVID-19)
  • null
    Multiplex technology allows for the detection of multiple targets from a single patient sample
  • null
    All reagents are on-board vivalytic cartridges
  • null
    Vivalytic cartridges are capable of target detection from multiple sample types Urine, Nasopharyngeal or Oropharyngeal Swab & Sputum
  • null
    Vivalytic cartridges are suitable for use at room temperature
  • null
    Vivalytic cartridges provide users with minimal risk contamination

Vivalytic cartridges are compact, technologically advanced Molecular Diagnostic tests utilising micro-fluidics to enable simple and accurate diagnostic testing. Vivalytic cartridges are powered by a variety of technologies, dependent upon the test application. Hi-Plex and Lo-Plex tests can be analysed on the Vivalytic. Hi-Plex tests utilise Randox patented Biochip Array Technology, enabling end-point qualitative PCR and providing multiple test results from each sample. Lo-Plex tests are based on a variety of detection methods including real-time qualitative PCR and melting curve analysis.

Randox patented Biochip Technology allows simultaneous detection of multiple targets from a single patient sample. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction. Each biochip is prefabricated with spatially discrete testing regions (DTR’s).

Each DTR represents an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest. The Hi-Plex capabilities of Biochip Technology eliminates the need to run multiple time consuming and sample intensive assays.

An enzyme is used to catalyse the chemical reaction of the biochip which generates the chemiluminescent signal. The light emitted from the chemiluminescent reaction that takes place in each DTR is simultaneously detected and quantified using a Charge – Coupled Device (CCD) Camera. This CCD Camera simultaneously records the light emission from all the DTRs on each biochip. The Vivalytic automatically generates a result report for all targets.

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

SARS-CoV-2 Rapid Test

VRI Array

Vivalytic

Vivalytic Test Menu


Vivalytic | SARS-CoV-2 Rapid 39 Minute Test

Vivalytic | SARS-CoV-2 Rapid 39 Minute Test

Detecting SARS-CoV-2 (COVID-19)

Rapidly Detecting SARS-CoV-2 (COVID-19)

  • null
    Detection from real-time PCR via Nasopharyngeal and/or Oropharyngeal swab
  • null
    The SARS-CoV-2 rapid test targets the E gene sequence for COVID-19 detection
  • null
    The SARS-CoV-2 rapid test has recently received CE marking
  • null
    Simple and easy to use analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
  • null
    Rapid turnaround time of just 39 mins from sample entry to result
  • null
    Convenient 4 step process from sample entry to results. No laboratory training required

SARS-CoV-2 (COVID-19) is a rapid real time PCR test cartridge, providing clear and concise results in a timely manner, direct at the point of care. This enables the patient to take the recommended safety precautions without delay.

In collaboration with Bosch, we are proud to release not only a rapid testing solution for the detection of SARS-CoV-2 (COVID-19) but an accelerated mass testing solution to effectively and efficiently monitor and detect viral infection from the offset with an aim of minimising the rise in infections globally. The new SARS-CoV-2 pooling test will allow users to test up to 160 samples a day and has sensitivity of 98% and a specificity of 100% – a world’s first!

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

SARS-CoV-2 Pooling Test

Vivalytic

Vivalytic Test Menu


Vivalytic | The All in One Molecular Solution

Vivalytic | All In One Molecular Solution

Molecular Diagnostics at the Point of Care

Why Choose the Vivalytic?

  • null
    Fully automated, sample to answer point of care diagnostics
  • null
    Full molecular workflow consolidated into one small benchtop platform
  • null
    Unique test menu covering a diverse range of respiratory, genitourinary and hospital acquired infections including SARS-CoV-2 (COVID-19)
  • null
    Hi-Plex & Lo-Plex Capabilities. Powered by Randox Biochip Technology enabling multiple results from one patient sample
  • null
    Wireless connectivity, no peripherals required making Vivalytic a unique space-saving & hygienic solution
  • null
    Easy 4 step process from sample entry to results. No laboratory training required
The Vivalytic platform is a universal, fully automated all in one solution for molecular diagnostics. It is a cartridge-based platform enabling Hi-Plex and Lo-Plex testing developed in partnership with Bosch. Vivalytic consolidates the full molecular workflow into a small benchtop platform, capable of extraction, PCR amplification and detection. Randox multiplex Biochip Technology powers Vivalytic enabling multiple results from one patient sample. Randox patented Biochip Technology allows simultaneous detection of multiple targets from a single patient sample. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction. Each biochip is prefabricated with spatially discrete testing regions (DTR’s). Each DTR represents an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest. The Hi-Plex capabilities of Biochip Technology eliminates the need to run multiple time consuming and sample intensive assays.

Vivalytic Test Menu

  • Virial Respiratory Infection
  • SARS-CoV-2 Rapid Test
  • SARS-CoV-2 Pooling
  • Respiratory Tract Infection
  • Flu A, B, & RSV
  • Chronic Lung Disease
  • STI
  • Urinary Tract Infection
  • MRSA

VIRUSES
SARS-CoV-2 (COVID-19)Sarbecovirus
(SARS, SARS like, SARS-CoV-2)
Influenza A
Coronavirus 229E/NL63Adenovirus A/B/C/D/EInfluenza B
Coronavirus OC43/HKUIEnterovirus A/B/CRhinovirus A/B
Middle East Respiratory
Syndrome Coronavirus (MERS-CoV)
VIRUSES
SARS-CoV-2 (COVID-19)
VIRUSES
SARS-CoV-2 (COVID-19)

 

VIRUSES
Influenza ACoronavirus OC43/HKUIParainfluenza virus 3
Influenza BEnterovirus A/B/CParainfluenza virus 4
Adenovirus A/B/C/D/EMetapneumovirusRespiratory syncytial virus A/B
Bocavirus 1/2/3Parainfluenza virus 1Rhinovirus A/B/C
Coronavirus 229E/NL63Parainfluenza virus 2
BACTERIA
Bordetella parapertussis Haemophilus influenzaeMycoplasma pneumoniae
Bordetella pertussisLegionella pneumophilaStreptococcus pneumoniae
Chlamydophila pneumoniaeMoraxella catarrhalis
VIRUSES
Influenza AInfluenza BRespiratory Syncytial Virus (RSV)
VIRUSES
AdenovirusRespiratory syncytial virus BInfluenza B
MetapneumovirusRhinovirus A/B/C
Respiratory syncytial virus AInfluenza virus A
BACTERIA
Achromobacter xylosoxidans Moraxella catarrhalis Pseudomonas aeruginosa
Bordetella pertussis Mycoplasma pneumoniae Staphylococcus aureus
Burkholderia cepacia complex (21 spp) Non-tuberculous mycobacterium (15 spp Stenotrophomonas maltophila
Burkholderia Cenocepacia Mycobacterium abscessus subgroup (4 spp) Streptococcus pneumoniae (21spp)
Burkholderia multivorans Mycobacterium avium complex (4 spp) Streptococcus species (19 spp)
Chlamydia pneumoniae Pandoraea species (5spp) Veillonella species (3 spp)
Haemophilus influenza Prevotella species (16 spp)
FUNGI
Aspergillus fumigatus Candida albicans Exophialia dermatitidis
Scedosporium species (7 spp)
ANTIBIOTIC RESISTANCE MARKERS
mecA (incl MRSA)
VIRUSES
Neisseria Gonorrhoeae (NG)Haemophilus Ducreyi (HD)
Mycoplasma Genitalium (MG)Mycoplasma Hominis (MH)
Ureaplasma Urealyticum (UU)Treponema Pallidum (TP)
Chlamydia Trachomatis (CT)Herpes Simplex virus 1(HSV-1)
Trichomonas Vaginalis (TV)Herpes Simplex virus 2(HSV-2)
BACTERIA
Citrobacter freundii Klebsiella oxytoca Serratia marcescens
Citrobacter koseri Klebsiella pneumoniae Staphylococcus aureus
Klebsiella aerogenes Morganella morganii Staphylococcus epidermidis
Enterobacter cloacae Proteus spp. Staphylococcus saprophyticus
Enterococcus faecalis Pseudomonas aeruginosa Streptococcus agalactiae (GBS)
Enterococcus faecium Providencia rettgeri
FUNGUS
Candida albicans
ANTIOBIOTIC RESISTANCE MARKERS
mecA (incl MRSA) Trimethoprim Resistance 3 Van A (Vancomycin Resistance A)
Trimethoprim Resistance 1 Trimethoprim Resistance 4 Van B (Vancomycin Resistance B)
Trimethoprim Resistance 2 Trimethoprim Resistance 5
BACTERIA
Methicillin-resistant Staphylococcus aureus (MRSA)Methicillin-sensitive Staphylococcus aureus (MSSA) Methicillin-resistant coagulase-negative Staphylococci (MRCoNS)

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

VRI Array

SARS-CoV-2 Rapid Test

SARS-CoV-2 Pooling Test

Vivalytic Test Menu


Vivalytic | Viral Respiratory Infection Array

Vivalytic | 10-Plex Viral Respiratory Infection Array

Detecting SARS-CoV-2 (COVID-19)

Detecting SARS-CoV-2 (COVID-19)

  • null
    Detection of up to 10 viral targets simultaneously from a single patient sample in 2.5 hours
  • null
    Full molecular workflow consolidated into one small benchtop platform
  • null
    Comprises sarbecovirus as a confirmatory target accurately diagnosing COVID-19
  • null
    Powered by Randox Biochip Technology enabling multiple results from one patient sample
  • null
    Target genes in line with WHO & CDC recommendations
  • null
    Easy 4 step process from sample entry to results. No laboratory training required.

The new Viral Respiratory Infection Array (VRI) will be conducted on Vivalytic, a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The VRI test can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.

Vivalytic cartridges are compact, technologically advanced Molecular Diagnostic tests utilising micro-fluidics to enable simple and accurate diagnostic testing. Randox patented Biochip Array Technology powers Vivalytic, enabling end-point qualitative PCR and providing multiple test results from each sample.

 

 

Viral Respiratory Infection Array (10-plex)

VIRUSES
SARS-CoV-2 (COVID-19)Sarbecovirus
(SARS, SARS like, SARS-CoV-2)
Influenza A
Coronavirus 229E/NL63Adenovirus A/B/C/D/EInfluenza B
Coronavirus OC43/HKUIEnterovirus A/B/CRhinovirus A/B
Middle East Respiratory
Syndrome Coronavirus (MERS-CoV)

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

SARS-CoV-2 Rapid Test

SARS-CoV-2 Pooling Test

Vivalytic

Vivalytic Test Menu


Norbrook partners with Randox on staff screening programme for COVID-19

News       About Us       COVID-19

 

27 May 2020

Norbrook partners with Randox on staff screening programme for COVID-19

Pharmaceuticals company Norbrook Laboratories has revealed that it will be the first company in Northern Ireland to install an innovative COVID-19 testing platform for on-site staff screening.

The Newry-based firm, which specialises in the development of pharmaceuticals for the veterinary industry, will begin testing for its workforce in the coming weeks, to provide reassurance and peace of mind for colleagues and for their families, without impacting on the public health need.

The COVID-19 screening programme at Norbrook is being facilitated by diagnostic technology from global diagnostics company Randox, one of the partners within the national COVID-19 testing programme.

David Ferguson, Managing Director at Randox Food Diagnostics explained;

“Collectively we are all working towards a timely return to a more normal society, which will see companies reopening and people returning to work.

“To facilitate this recovery of the economy, without compromising the health of workers or of the wider general public, workplaces have a responsibility to provide a safe working environment.

“We know that the health of Norbrook’s staff is their priority and as such it is great to see them taking a proactive approach to testing.”

The COVID-19 screening programme at Norbrook is the first in Northern Ireland being facilitated by an innovative testing platform capable of processing results in 2hours 30 mins.

The technology, named the Vivalytic, can screen for SARS-CoV-2, the virus that causes COVID-19, as well as a range of other viral and bacterial infections including Influenza A and B, Pneumonia and other coronaviruses.

David added;

“Randox is fully committed to supporting the national effort to fight COVID-19 by testing at scale, and as we continue to work alongside the government and ramp up our testing capabilities, we welcome the fact that other organisations are also adopting our innovative COVID-19 testing technologies to address their own particular testing needs.

“The Vivalytic, which provides high quality molecular testing for COVID-19, on-site and without the need for laboratory experience, is a unique space-saving, hygienic solution for personnel COVID-19 testing in any setting and will help a wide variety of industries get back to business by ensuring the highest level of safety.”

Denise Collins, Norbrook Human Resources Director, concluded;

“We’re proud to be working with a company like Randox which has such vast experience in the diagnostics industry and was subsequently able to respond so quickly to the COVID-19 pandemic.

“That this world-leading technology is available from a Northern Ireland-headquartered company presents a unique opportunity for workplaces here to quickly and easily implement a staff screening programme, and at the same time demonstrate a high standard of duty of care that should be shown by employers to their employees.”

For further information about the Vivalytic please email marketing@randox.com

 

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our Randox Products and Services

REAGENTS

RX SERIES

ACUSERA

BIOCHIP


Point of care coronavirus test from Randox and Bosch will launch in April 2020

News       About Us        Randox Biosciences

26 March 2020

 

Vivalytic Viral Respiratory Tract Infection Array Detecting SARS-CoV-2 (COVID-19)

A game-changing point of care coronavirus test from global diagnostics company Randox Laboratories and leading technology manufacturer Bosch Healthcare Solutions will launch in April 2020.

The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.

This provides a more comprehensive respiratory screening which enables precise and informed treatment decisions to be made.

Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences, commented;

“This array focuses not only on the identification of the novel coronavirus strain that causes COVID-19, but also nine other respiratory infection targets simultaneously, including Influenza A and B, Sarbecovirus and MERS. The aim is to diagnose patients fast and accurately from a single genetic sample, maximising containment of the virus whilst minimising the spread. With the development of this array onto a fully automated platform, patients can be diagnosed rapidly at point of care locations globally such as pharmacies and doctor surgeries.”

The Viral Respiratory Tract Infection Array is one of the world’s first multiplex molecular diagnostic tests meeting the COVID-19 testing recommendations of the World Health Organisation (WHO) and the Centres for Disease Control (CDC).

The target genes for COVID-19 being used on the VRI array represent conserved regions of the genome which have been chosen for their high sensitivity and specificity.

Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said:

“We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”

The new VRI test will be conducted on Vivalytic a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed which minimises the risk of contamination, require room temperature storage (space-saving), contain all the reagents on-board the cartridge and utilises end point PCR.  The test only requires a single nasal swab from the patient and an easy four step process to be carried out by the user to run the patient sample.

 

Key Benefits of Vivalytic | Point of Care Platform

  • Fully-automated
  • User friendly
  • No laboratory training required
  • 4 step work flow
  • Minimal contamination risk – fully contained system
  • No peripherals required – hygienic
  • Touchscreen
  • Connects to LIMS (Laboratory Information Management System)
  • Sample Type: Nasopharyngeal Swab
  • Sample Volume: 300µl clinical sample

For more information or to arrange interviews, please contact info@randoxbiosciences.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×